BCAX

Bicara Therapeutics Inc. Common Stock

Insider Trades

NameValueActionPriceCurrent Price
Hyep IvanChief Financial Officer
$188k9.2k shares
SellMay 21, 2026
$20.42
--
Mazumdar ClaireDirector, Officer: Chief Executive Officer
$240k12k shares
SellMay 18, 2026
$19.96
--
Mazumdar ClaireDirector, Officer: Chief Executive Officer
$61k3k shares
SellMay 18, 2026
$20.35
--
Cohlhepp RyanDirector, Officer: President And COO
$162k8k shares
SellMay 15, 2026
$20.29
--
Cohlhepp RyanDirector, Officer: President And COO
$91k4.5k shares
SellMay 15, 2026
$20.29
--
Raben DavidChief Medical Officer
$126k5.5k shares
SellApr 27, 2026
$22.88
--

News

fool.comWhat Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?fool.comJun 13seekingalpha.comBicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negative Head and Neck Cancer at ASCO Transcriptseekingalpha.comMay 22marketbeat.comBicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancermarketbeat.comMay 22globenewswire.comFicerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCCglobenewswire.comMay 21fool.comBicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Betfool.comMay 15